277 results on '"Kullak-Ublick, GA."'
Search Results
2. Mechanism for anti-inflammatory effects of Farnesiferol B in ischemia/reperfusion injury of kidney
- Author
-
Zhang, L, additional, Fu, X, additional, Wang, T, additional, Wang, Z, additional, Gai, Z, additional, and Kullak-Ublick, GA, additional
- Published
- 2019
- Full Text
- View/download PDF
3. Induction of PCFT and OATP1A2 via vitamin D receptor activation in vitro is not confirmed in vivo in healthy volunteers after a 10-days treatment with 1,25-dihydroxyvitamin D3
- Author
-
Marti, I, Claro da Silva, T, Spanaus, K, Gubler, C, Kullak-Ublick, GA, and Jetter, A
- Subjects
ddc: 610 ,610 Medical sciences ,Medicine - Abstract
Aim: In humans, intestinal uptake of folic acid is mainly mediated by the proton-coupled folate transporter PCFT. In Caco-2 cells, the cellular uptake of folate via PCFT can be increased between 2- and 4-fold by a three-day treatment with 1,25-dihydroxyvitamin D3. Additionally, mRNA content and protein[for full text, please go to the a.m. URL], 16. Jahreskongress für Klinische Pharmakologie
- Published
- 2014
- Full Text
- View/download PDF
4. Too frequent low-dose methotrexate prescriptions: multicentre quality control and quality assurance with pre- and post-analysis
- Author
-
Karlen, S, primary, Oertle, M, additional, Weiler, S, additional, Schneemann, M, additional, Eschmann, E, additional, Kullak-Ublick, GA, additional, and Blaser, J, additional
- Published
- 2015
- Full Text
- View/download PDF
5. Einfluss proinflammatorischer Zytokine auf die Transkriptionsfaktoren hepatobiliärer organischer Aniontransporter bei toxischem Leberschaden und Cholestase
- Author
-
Geier, A, primary, Dietrich, CG, additional, Voigt, S, additional, Kim, SK, additional, Gerloff, T, additional, Kullak-Ublick, GA, additional, Matern, S, additional, and Gartung, C, additional
- Published
- 2015
- Full Text
- View/download PDF
6. [Management of ulcerative colitis]
- Author
-
Kullak-Ublick Ga and Rammert Ch
- Subjects
Time Factors ,Hydrocortisone ,medicine.medical_treatment ,Anti-Inflammatory Agents ,Administration, Oral ,Placebos ,Remission induction ,0302 clinical medicine ,Adrenal Cortex Hormones ,Recurrence ,Risk Factors ,Azathioprine ,030212 general & internal medicine ,Budesonide ,Mesalamine ,Colectomy ,Clinical Trials as Topic ,Management of ulcerative colitis ,Mercaptopurine ,Anti-Inflammatory Agents, Non-Steroidal ,Remission Induction ,Antibodies, Monoclonal ,Anemia ,General Medicine ,Colonoscopy ,3. Good health ,030220 oncology & carcinogenesis ,Injections, Intravenous ,Practice Guidelines as Topic ,Colorectal Neoplasms ,Immunosuppressive Agents ,medicine.drug ,medicine.medical_specialty ,Colonic Pouches ,Cyclosporins ,Antiviral Agents ,03 medical and health sciences ,Gastrointestinal Agents ,medicine ,Humans ,Colitis ,Gynecology ,business.industry ,Suppositories ,medicine.disease ,Infliximab ,Aminosalicylic Acids ,Osteoporosis ,Colitis, Ulcerative ,Interferons ,business - Abstract
Die Colitis ulcerosa ist eine chronisch-entzündliche Darmerkrankung, die aufgrund klinischer Parameter sowie des endoskopisch-histologischen Befundes diagnostiziert wird. Moderne 5-Aminosalizylate (5-ASA) nehmen die zentrale Rolle in der Behandlung ein. Sofern die Ausdehnung der Kolitis die linke Kolonflexur nicht überschreitet, sind rektale Applikationsformen vorzuziehen. Neben 5-ASA-Suppositorien und -Klysmen kommen topisch wirksame Kortikosteroide wie Budesonidklysmen und Hydrocortisonschäume zum Einsatz. Geht die Entzündung über die linke Flexur hinaus, muss eine orale Medikation erfolgen. Bei gering- bis mäßiggradiger Entzündung sind 5-ASA-Präparate die Therapie der ersten Wahl. Bei höhergradiger Entzündung werden Steroide eingesetzt. Nach erfolgter Remission sollte zur Rezidivprophylaxe 5-ASA (1,5 g/d) eingenommen werden. Bei häufig rezidivierenden Schüben oder Steroidabhängigkeit stellt sich die Indikation zur Behandlung mit den Immunmodulatoren Azathioprin oder 6-Mercaptopurin. Bei fulminanten Verläufen wird zunächst ein Versuch mit einer intravenösen Hochdosissteroidtherapie unternommen. Bei Versagen dieser Therapie kann Ciclosporin eingesetzt werden. Als ultima Ratio bei Erfolglosigkeit der konservativen Maßnahmen bleibt die Proktokolektomie mit Anlage eines ileoanalen Pouchs. Neuere Therapiemethoden wie Infliximab und Interferone befinden sich derzeit in klinischer Erprobung. Neben der Therapie der Grunderkrankung müssen mögliche Langzeitkomplikationen wie steroidbedingte Osteoporose und Anämie behandelt werden. Dem Risiko der Dysplasie- und Karzinomentwicklung muss nach langjährigem Krankheitsverlauf durch regelmäßige endoskopische Kontrollen Rechnung getragen werden.
- Published
- 2003
7. Tauroursodeoxycholic acid activates protein kinase C in isolated rat hepatocytes
- Author
-
G. Sauter, U. Beuers, H. G. Koebe, Anderson Ms, Carlos M. Isales, James L. Boyer, Kullak-Ublick Ga, Throckmorton Dc, Thasler W, G. Paumgartner, and Other departments
- Subjects
Male ,Taurocholic Acid ,Cholagogues and Choleretics ,medicine.medical_specialty ,medicine.drug_class ,Biology ,Exocytosis ,Diglycerides ,Rats, Sprague-Dawley ,Taurochenodeoxycholic Acid ,chemistry.chemical_compound ,Cytosol ,Internal medicine ,medicine ,Animals ,Cells, Cultured ,Protein Kinase C ,Protein kinase C ,Hepatology ,Bile acid ,Cell Membrane ,Gastroenterology ,Tauroursodeoxycholic acid ,Taurocholic acid ,Molecular biology ,Ursodeoxycholic acid ,Rats ,Enzyme Activation ,Isoenzymes ,Endocrinology ,medicine.anatomical_structure ,Liver ,chemistry ,Hepatocyte ,Phorbol ,Liver function ,medicine.drug - Abstract
BACKGROUND & AIMS: Ursodeoxycholic acid (UDCA) improves liver function in patients with chronic cholestatic liver diseases by an unknown mechanism. UDCA is conjugated to taurine in vivo, and tauroursodeoxycholic acid (TUDCA) is a potent hepatocellular Ca2+ agonist and stimulates biliary exocytosis and hepatocellular Ca2+ influx, both of which are defective in experimental cholestasis. Protein kinase C (PKC) mediates stimulation of exocytosis in the liver. The aim of this study was to determine the effects of TUDCA on PKC in isolated hepatocytes. METHODS: The effect of TUDCA on the distribution of PKC isoenzymes within the hepatocyte was studied using immunoblotting and immunofluorescence techniques. In addition, the effect of TUDCA on the accummulation of sn-1,2-diacylglycerol (DAG), the intracellular activator of PKC, and hepatocellular PKC activity was studied using radioenzymatic techniques. RESULTS: Immunoblotting studies showed the presence of four isoenzymes (alpha, delta, epsilon, and zeta). The phorbol ester phorbol 12-myristate 13-acetate (1 mumol/L) induced translocation of alpha-PKC, delta-PKC, and epsilon-PKC from cytosol to a particulate membrane fraction, a key step for activation of PKC. TUDCA, but not taurocholic acid, selectively induced translocation of the alpha-PKC isoenzyme from cytosol to the membranes. In addition, TUDCA induced a significant increase in hepatocellular DAG mass and stimulated membrane-associated PKC activity. CONCLUSIONS: TUDCA might stimulate Ca(2+)-dependent hepatocellular exocytosis into bile in part by activation of alpha-PKC. (Gastroenterology 1996 May;110(5):1553-63)
- Published
- 1996
8. Comparative performance of two drug interaction screening programs analyzing a cross-sectional prescription dataset of 84,625 psychiatric inpatients
- Author
-
Zorina, OL, primary, Haueis, P, additional, Greil, W, additional, Grohmann, R, additional, Kullak-Ublick, GA, additional, and Russmann, S, additional
- Published
- 2012
- Full Text
- View/download PDF
9. Roflumilast - a phosphodiesterase-4 inhibitor licensed for add-on therapy in severe COPD
- Author
-
Taegtmeyer, AB, primary, Leuppi, JD, additional, and Kullak-Ublick, GA, additional
- Published
- 2012
- Full Text
- View/download PDF
10. Drug-related problems and factors influencing acceptance of clinical pharmacologists` alerts in a large cohort of neurology inpatients
- Author
-
Taegtmeyer, AB, primary, Curkovic, I, additional, Corti, N, additional, Rosen, C, additional, Egbring, M, additional, Russmann, S, additional, Gantenbein, AR, additional, Weller, M, additional, and Kullak-Ublick, GA, additional
- Published
- 2012
- Full Text
- View/download PDF
11. Inhibition der Hepatitis C-Virustranslation durch Gallensäure-gekoppelte antisense Oligodeoxynukleotide
- Author
-
Gonzalez-Carmona, MA, primary, Quasdorff, M, additional, Tamke, A, additional, Hoffman, P, additional, Lehmann, T, additional, Engels, JW, additional, Kullak-Ublick, GA, additional, Sauerbruch, T, additional, and Caselmann, WH, additional
- Published
- 2004
- Full Text
- View/download PDF
12. First clinical experience with Molecular Adsorbent Recirculating System (MARS) in six patients with severe acute on chronic liver failure
- Author
-
Mullhaupt, B, primary, Kullak‐Ublick, GA, additional, Ambühl, P, additional, Maggiorini, M, additional, Stocker, R, additional, Kadry, Z, additional, Clavien, PA, additional, Renner, EL., additional, Mullhaupt, B., additional, Kullak‐Ublick, G. A., additional, Ambühl, P., additional, Maggiorini, M., additional, Stocker, R., additional, Kadry, Z., additional, Clavien, P. A., additional, and Renner, E. L., additional
- Published
- 2002
- Full Text
- View/download PDF
13. Chlorambucil-taurocholate is transported by bile acid carriers expressed in human hepatocellular carcinomas
- Author
-
Kullak-Ublick, GA, primary, Glasa, J, additional, Boker, C, additional, Oswald, M, additional, Grutzner, U, additional, Hagenbuch, B, additional, Stieger, B, additional, Meier, PJ, additional, Beuers, U, additional, Kramer, W, additional, Wess, G, additional, and Paumgartner, G, additional
- Published
- 1997
- Full Text
- View/download PDF
14. Safety and efficacy of repeated shockwave lithotripsy of gallstones with and without adjuvant bile acid therapy
- Author
-
Sauter, G, primary, Kullak-Ublick, GA, additional, Schumacher, R, additional, Janssen, J, additional, Greiner, L, additional, Brand, B, additional, Stange, EF, additional, Wengler, K, additional, Lochs, H, additional, Freytag, A, additional, Wissing, A, additional, Holl, J, additional, Sackmann, M, additional, and Paumgartner, G, additional
- Published
- 1997
- Full Text
- View/download PDF
15. 7 alpha-dehydroxylating bacteria enhance deoxycholic acid input and cholesterol saturation of bile in patients with gallstones
- Author
-
Berr, F, primary, Kullak-Ublick, GA, additional, Paumgartner, G, additional, Munzing, W, additional, and Hylemon, PB, additional
- Published
- 1996
- Full Text
- View/download PDF
16. Tauroursodeoxycholic acid activates protein kinase C in isolated rat hepatocytes
- Author
-
Beuers, U, primary, Throckmorton, DC, additional, Anderson, MS, additional, Isales, CM, additional, Thasler, W, additional, Kullak-Ublick, GA, additional, Sauter, G, additional, Koebe, HG, additional, Paumgartner, G, additional, and Boyer, JL, additional
- Published
- 1996
- Full Text
- View/download PDF
17. Therapeutic drug monitoring of thiopurine drugs in patients with inflammatory bowel disease or autoimmune hepatitis.
- Author
-
Wusk B, Kullak-Ublick GA, Rammert C, von Eckardstein A, Fried M, Rentsch KM, Wusk, Barbara, Kullak-Ublick, Gerd A, Rammert, Christina, von Eckardstein, Arnold, Fried, Michael, and Rentsch, Katharina M
- Published
- 2004
- Full Text
- View/download PDF
18. Cohort profile: the Swiss Inflammatory Bowel Disease Cohort Study (SIBDCS)
- Author
-
Pittet, V, Juillerat, P, Mottet, C, Felley, C, Ballabeni, P, Burnand, B, Michetti, P, Vader, JP, and, the Swiss IBD Cohort Study Group, Swiss IBD Cohort Study Group, Michetti, P., Vader, JP., Burnand, B., Pittet, V., Ballabeni, P., Mueller, C., Rihs, S., Braegger, C., Mottet, C., Juillerat, P., Felley, C., Beglinger, C., Froehlich, F., Vavricka, S., Seibold, F., Schoepfer, A., von Känel, R., Begré, S., de Saussure, P., Meyenberger, C., Sagmeister, M., Rogler, G., Kullak-Ublick, GA., Meier, R., Straumann, A., Criblez, D., Engelmann, M., Schenk, M., University of Zurich, and Pittet, V
- Subjects
medicine.medical_specialty ,Pediatrics ,Biological Specimen Banks ,Cohort Studies ,Humans ,Inflammatory Bowel Diseases/epidemiology ,Inflammatory Bowel Diseases/etiology ,Patient Dropouts/statistics & numerical data ,Patient Selection ,Risk Factors ,Switzerland/epidemiology ,Patient Dropouts ,Epidemiology ,610 Medicine & health ,Disease ,Inflammatory bowel disease ,03 medical and health sciences ,Indirect costs ,0302 clinical medicine ,Medicine ,business.industry ,General Medicine ,medicine.disease ,Inflammatory Bowel Diseases ,Family life ,3. Good health ,Surgery ,10219 Clinic for Gastroenterology and Hepatology ,10036 Medical Clinic ,030220 oncology & carcinogenesis ,Cohort ,Absenteeism ,030211 gastroenterology & hepatology ,business ,Switzerland ,Cohort study ,2713 Epidemiology - Abstract
already in the first or second decade of life, while patients are either in full-time education or just entering the workforce. The negative impact on social life or ability to achieve, either scholastically or professionally, can severely affect professional as well as family life. Indeed, 450% of patients with Crohn’s disease indicate that their disease has an influence on their professional and personal life. 6 The course of the disease is often characterized by progressive worsening of the patient’s condition, with increasing frequency of hospitalization and considerable indirect costs through absenteeism and disability allowances. 7 Disease activity is known to be
- Published
- 2009
- Full Text
- View/download PDF
19. Identification of reversible OATP1B1 and time-dependent CYP3A4 inhibition as the major risk factors for drug-induced cholestasis (DIC).
- Author
-
Kastrinou-Lampou V, Rodríguez-Pérez R, Poller B, Huth F, Gáborik Z, Mártonné-Tóth B, Temesszentandrási-Ambrus C, Schadt HS, Kullak-Ublick GA, Arand M, and Camenisch G
- Subjects
- Humans, Risk Factors, Bile Acids and Salts metabolism, Cytochrome P-450 CYP3A Inhibitors, Time Factors, Cholestasis chemically induced, Cholestasis metabolism, Liver-Specific Organic Anion Transporter 1 metabolism, Cytochrome P-450 CYP3A metabolism, Chemical and Drug Induced Liver Injury etiology
- Abstract
Hepatic bile acid regulation is a multifaceted process modulated by several hepatic transporters and enzymes. Drug-induced cholestasis (DIC), a main type of drug-induced liver injury (DILI), denotes any drug-mediated condition in which hepatic bile flow is impaired. Our ability in translating preclinical toxicological findings to human DIC risk is currently very limited, mainly due to important interspecies differences. Accordingly, the anticipation of clinical DIC with available in vitro or in silico models is also challenging, due to the complexity of the bile acid homeostasis. Herein, we assessed the in vitro inhibition potential of 47 marketed drugs with various degrees of reported DILI severity towards all metabolic and transport mechanisms currently known to be involved in the hepatic regulation of bile acids. The reported DILI concern and/or cholestatic annotation correlated with the number of investigated processes being inhibited. Furthermore, we employed univariate and multivariate statistical methods to determine the important processes for DILI discrimination. We identified time-dependent inhibition (TDI) of cytochrome P450 (CYP) 3A4 and reversible inhibition of the organic anion transporting polypeptide (OATP) 1B1 as the major risk factors for DIC among the tested mechanisms related to bile acid transport and metabolism. These results were consistent across multiple statistical methods and DILI classification systems applied in our dataset. We anticipate that our assessment of the two most important processes in the development of cholestasis will enable a risk assessment for DIC to be efficiently integrated into the preclinical development process., (© 2024. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.)
- Published
- 2024
- Full Text
- View/download PDF
20. L-carnitine co-administration prevents colistin-induced mitochondrial permeability transition and reduces the risk of acute kidney injury in mice.
- Author
-
Samodelov SL, Gai Z, De Luca F, Haldimann K, Hobbie SN, Müller D, Kullak-Ublick GA, and Visentin M
- Subjects
- Animals, Mice, Male, Mitochondrial Permeability Transition Pore metabolism, Kidney drug effects, Kidney metabolism, Kidney pathology, Mice, Inbred C57BL, Cyclosporine, Colistin adverse effects, Colistin administration & dosage, Acute Kidney Injury prevention & control, Acute Kidney Injury chemically induced, Acute Kidney Injury metabolism, Carnitine pharmacology, Carnitine administration & dosage, Mitochondria drug effects, Mitochondria metabolism, Anti-Bacterial Agents pharmacology, Anti-Bacterial Agents administration & dosage
- Abstract
Colistin is a polymyxin antibiotic currently experiencing renewed clinical interest due to its efficacy in the treatment of multidrug resistant (MDR) bacterial infections. The frequent onset of acute dose-dependent kidney injury, with the potential of leading to long-term renal damage, has limited its use and hampered adequate dosing regimens, increasing the risk of suboptimal plasma concentrations during treatment. The mechanism of colistin-induced renal toxicity has been postulated to stem from mitochondrial damage, yet there is no direct evidence of colistin acting as a mitochondrial toxin. The aim of this study was to evaluate whether colistin can directly induce mitochondrial toxicity and, if so, uncover the underlying molecular mechanism. We found that colistin leads to a rapid permeability transition of mitochondria isolated from mouse kidney that was fully prevented by co-incubation of the mitochondria with desensitizers of the mitochondrial transition pore cyclosporin A or L-carnitine. The protective effect of L-carnitine was confirmed in experiments in primary cultured mouse tubular cells. Consistently, the relative risk of colistin-induced kidney damage, calculated based on histological analysis as well as by the early marker of tubular kidney injury, Kim-1, was halved under co-administration with L-carnitine in vivo. Notably, L-carnitine neither affected the pharmacokinetics of colistin nor its antimicrobial activity against relevant bacterial strains. In conclusion, colistin targets the mitochondria and induces permeability transition thereof. L-carnitine prevents colistin-induced permeability transition in vitro. Moreover, L-carnitine co-administration confers partial nephroprotection in mice treated with colistin, without interfering with its pharmacokinetics and antibacterial activity., (© 2024. The Author(s).)
- Published
- 2024
- Full Text
- View/download PDF
21. Impact of Electronic Patient-Reported Outcomes on Unplanned Consultations and Hospitalizations in Patients With Cancer Undergoing Systemic Therapy: Results of a Patient-Reported Outcome Study Compared With Matched Retrospective Data.
- Author
-
Trojan A, Kühne C, Kiessling M, Schumacher J, Dröse S, Singer C, Jackisch C, Thomssen C, and Kullak-Ublick GA
- Abstract
Background: The evaluation of electronic patient-reported outcomes (ePROs) is increasingly being used in clinical studies of patients with cancer and enables structured and standardized data collection in patients' everyday lives. So far, few studies or analyses have focused on the medical benefit of ePROs for patients., Objective: The current exploratory analysis aimed to obtain an initial indication of whether the use of the Consilium Care app (recently renamed medidux; mobile Health AG) for structured and regular self-assessment of side effects by ePROs had a recognizable effect on incidences of unplanned consultations and hospitalizations of patients with cancer compared to a control group in a real-world care setting without app use. To analyze this, the incidences of unplanned consultations and hospitalizations of patients with cancer using the Consilium Care app that were recorded by the treating physicians as part of the patient reported outcome (PRO) study were compared retrospectively to corresponding data from a comparable population of patients with cancer collected at 2 Swiss oncology centers during standard-of-care treatment., Methods: Patients with cancer in the PRO study (178 included in this analysis) receiving systemic therapy in a neoadjuvant or noncurative setting performed a self-assessment of side effects via the Consilium Care app over an observational period of 90 days. In this period, unplanned (emergency) consultations and hospitalizations were documented by the participating physicians. The incidence of these events was compared with retrospective data obtained from 2 Swiss tumor centers for a matched cohort of patients with cancer., Results: Both patient groups were comparable in terms of age and gender ratio, as well as the distribution of cancer entities and Joint Committee on Cancer stages. In total, 139 patients from each group were treated with chemotherapy and 39 with other therapies. Looking at all patients, no significant difference in events per patient was found between the Consilium group and the control group (odds ratio 0.742, 90% CI 0.455-1.206). However, a multivariate regression model revealed that the interaction term between the Consilium group and the factor "chemotherapy" was significant at the 5% level (P=.048). This motivated a corresponding subgroup analysis that indicated a relevant reduction of the risk for the intervention group in the subgroup of patients who underwent chemotherapy. The corresponding odds ratio of 0.53, 90% CI 0.288-0.957 is equivalent to a halving of the risk for patients in the Consilium group and suggests a clinically relevant effect that is significant at a 2-sided 10% level (P=.08, Fisher exact test)., Conclusions: A comparison of unplanned consultations and hospitalizations from the PRO study with retrospective data from a comparable cohort of patients with cancer suggests a positive effect of regular app-based ePROs for patients receiving chemotherapy. These data are to be verified in the ongoing randomized PRO2 study (registered on ClinicalTrials.gov; NCT05425550)., Trial Registration: ClinicalTrials.gov NCT03578731; https://www.clinicaltrials.gov/ct2/show/NCT03578731., International Registered Report Identifier (irrid): RR2-10.2196/29271., (©Andreas Trojan, Christian Kühne, Michael Kiessling, Johannes Schumacher, Stefan Dröse, Christian Singer, Christian Jackisch, Christoph Thomssen, Gerd A Kullak-Ublick. Originally published in JMIR Formative Research (https://formative.jmir.org), 06.05.2024.)
- Published
- 2024
- Full Text
- View/download PDF
22. Comparison of the Real-World Reporting of Symptoms and Well-Being for the HER2-Directed Trastuzumab Biosimilar Ogivri With Registry Data for Herceptin in the Treatment of Breast Cancer: Prospective Observational Study (OGIPRO) of Electronic Patient-Reported Outcomes.
- Author
-
Trojan A, Roth S, Atassi Z, Kiessling M, Zenhaeusern R, Kadvany Y, Schumacher J, Kullak-Ublick GA, Aapro M, and Eniu A
- Abstract
Background: Trastuzumab has had a major impact on the treatment of human epidermal growth factor receptor 2 (HER2)-positive breast cancer (BC). Anti-HER2 biosimilars such as Ogivri have demonstrated safety and clinical equivalence to trastuzumab (using Herceptin as the reference product) in clinical trials. To our knowledge, there has been no real-world report of the side effects and quality of life (QoL) in patients treated with biosimilars using electronic patient-reported outcomes (ePROs)., Objective: The primary objective of this prospective observational study (OGIPRO study) was to compare the ePRO data related to treatment side effects collected with the medidux app in patients with HER2-positive BC treated with the trastuzumab biosimilar Ogivri (prospective cohort) to those obtained from historical cohorts treated with Herceptin alone or combined with pertuzumab and/or chemotherapy (ClinicalTrials.gov NCT02004496 and NCT03578731)., Methods: Patients were treated with Ogivri alone or combined with pertuzumab and/or chemotherapy and hormone therapy in (neo)adjuvant and palliative settings. Patients used the medidux app to dynamically record symptoms (according to the Common Terminology Criteria for Adverse Events [CTCAE]), well-being (according to the Eastern Cooperative Oncology Group Performance Status scale), QoL (using the EQ-5D-5L questionnaire), cognitive capabilities, and vital parameters over 6 weeks. The primary endpoint was the mean CTCAE score. Key secondary endpoints included the mean well-being score. Data of this prospective cohort were compared with those of the historical cohorts (n=38 patients; median age 51, range 31-78 years)., Results: Overall, 53 female patients with a median age of 54 years (range 31-87 years) were enrolled in the OGIPRO study. The mean CTCAE score was analyzed in 50 patients with available data on symptoms, while the mean well-being score was evaluated in 52 patients with available data. The most common symptoms reported in both cohorts included fatigue, taste disorder, nausea, diarrhea, dry mucosa, joint discomfort, tingling, sleep disorder, headache, and appetite loss. Most patients experienced minimal (grade 0) or mild (grade 1) toxicities in both cohorts. The mean CTCAE score was comparable between the prospective and historical cohorts (29.0 and 30.3, respectively; mean difference -1.27, 95% CI -7.24 to 4.70; P=.68). Similarly, no significant difference was found for the mean well-being score between the groups treated with the trastuzumab biosimilar Ogivri and Herceptin (74.3 and 69.8, respectively; mean difference 4.45, 95% CI -3.53 to 12.44; P=.28)., Conclusions: Treatment of patients with HER2-positive BC with the trastuzumab biosimilar Ogivri resulted in equivalent symptoms, adverse events, and well-being as found for patients treated with Herceptin as determined by ePRO data. Hence, integration of an ePRO system into research and clinical practice can provide reliable information when investigating the real-world tolerability and outcomes of similar therapeutic compounds., Trial Registration: ClinicalTrials.gov NCT05234021; https://clinicaltrials.gov/study/NCT05234021., (©Andreas Trojan, Sven Roth, Ziad Atassi, Michael Kiessling, Reinhard Zenhaeusern, Yannick Kadvany, Johannes Schumacher, Gerd A Kullak-Ublick, Matti Aapro, Alexandru Eniu. Originally published in JMIR Cancer (https://cancer.jmir.org), 04.04.2024.)
- Published
- 2024
- Full Text
- View/download PDF
23. Liver toxicity in oncology trials and beyond: a simplified concept for management of hepatocellular drug-induced liver injury in patients with abnormal baseline liver tests.
- Author
-
Merz M, Fettiplace A, Marcinak J, Tillmann HL, Rockey DC, and Kullak-Ublick GA
- Subjects
- Humans, Alanine Transaminase, Liver, Carcinoma, Hepatocellular, Liver Neoplasms drug therapy, Chemical and Drug Induced Liver Injury diagnosis, Chemical and Drug Induced Liver Injury etiology, Drug-Related Side Effects and Adverse Reactions
- Abstract
Background: Management of side effects in clinical trials has to balance generation of meaningful data with risk for patients. A toxicity area requiring detailed management guidelines is drug-induced liver injury (DILI). In oncology trials, patients are often included despite baseline liver test abnormalities, for whom there is no consensus yet on levels of liver test changes that should trigger action, such as drug interruption or discontinuation., Methods: We provide an innovative approach to manage hepatocellular DILI in oncology trials for patients with abnormal baseline alanine aminotransferase (ALT) levels. The algorithm proposed is based on mathematical derivation of action thresholds from those generally accepted for patients with normal baselines., Results: The resulting algorithm is grouped by level of baseline abnormality and avoids calculation of baseline multiples. Suggested layered action levels are 4, 6, and 11 × Upper Limit of Normal (ULN) for patients with baseline ALT between 1.5 and 3 × ULN, and 6, 8, and 12 × ULN for patients with baseline ALT between 3 and 5 × ULN, respectively., Conclusions: Our concept and resulting algorithm are consistent, transparent, and easy to follow, and the method for derivation from consensus-based thresholds may also be applicable to other drug toxicity areas.
- Published
- 2024
- Full Text
- View/download PDF
24. Roadmap to DILI research in Europe. A proposal from COST action ProEuroDILINet.
- Author
-
Lucena MI, Villanueva-Paz M, Alvarez-Alvarez I, Aithal GP, Björnsson ES, Cakan-Akdogan G, Cubero FJ, Esteves F, Falcon-Perez JM, Fromenty B, Garcia-Ruiz C, Grove JI, Konu O, Kranendonk M, Kullak-Ublick GA, Miranda JP, Remesal-Doblado A, Sancho-Bru P, Nelson L, Andrade RJ, Daly AK, and Fernandez-Checa JC
- Subjects
- Humans, Europe, Forecasting, Databases, Factual, Chemical and Drug Induced Liver Injury, Drug-Related Side Effects and Adverse Reactions
- Abstract
In the current article the aims for a constructive way forward in Drug-Induced Liver Injury (DILI) are to highlight the most important priorities in research and clinical science, therefore supporting a more informed, focused, and better funded future for European DILI research. This Roadmap aims to identify key challenges, define a shared vision across all stakeholders for the opportunities to overcome these challenges and propose a high-quality research program to achieve progress on the prediction, prevention, diagnosis and management of this condition and impact on healthcare practice in the field of DILI. This will involve 1. Creation of a database encompassing optimised case report form for prospectively identified DILI cases with well-characterised controls with competing diagnoses, biological samples, and imaging data; 2. Establishing of preclinical models to improve the assessment and prediction of hepatotoxicity in humans to guide future drug safety testing; 3. Emphasis on implementation science and 4. Enhanced collaboration between drug-developers, clinicians and regulatory scientists. This proposed operational framework will advance DILI research and may bring together basic, applied, translational and clinical research in DILI., Competing Interests: Declaration of Competing Interest The authors have no conflict of interest to disclose in relation to this topic., (Copyright © 2024 The Authors. Published by Elsevier Ltd.. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF
25. Developing a Model for Quantifying QTc-Prolongation Risk to Enhance Medication Safety Assessment: A Retrospective Analysis.
- Author
-
Giovannoni L, Kullak-Ublick GA, and Jetter A
- Abstract
There are currently no established methods to predict quantitatively whether the start of a drug with the potential to prolong the QTc interval poses patients at risk for relevant QTc prolongation. Therefore, this retrospective study aimed to pave the way for the development of models for estimating QTc prolongation in patients newly exposed to medications with QTc-prolonging potential. Data of patients with a documented QTc prolongation after initiation of a QTc-prolonging drug were extracted from hospital charts. Using a standard model-building approach, general linear mixed models were identified as the best models for predicting both the extent of QTc prolongation and its absolute value after the start of a QTc-time-prolonging drug. The cohort consisted of 107 adults with a mean age of 64.2 years. Patients were taking an average of 2.4 drugs associated with QTc prolongation, with amiodarone, propofol, pipamperone, ondansetron, and mirtazapine being the most frequently involved. There was a significant but weak correlation between measured and predicted absolute QTc values under medication (r
2 = 0.262, p < 0.05), as well as for QTc prolongation (r2 = 0.238, p < 0.05). As the developed models are based on a relatively small number of subjects, further research is necessary to ensure their applicability and reliability in real-world scenarios. Overall, this research contributes to the understanding of QTc prolongation and its association with medications, providing insight into the development of predictive models. With improvements, these models could potentially aid healthcare professionals in assessing the risk of QTc prolongation before adding a new drug and in making informed decisions in clinical settings.- Published
- 2024
- Full Text
- View/download PDF
26. Patients with naproxen-induced liver injury display T-cell memory responses toward an oxidative (S)-O-desmethyl naproxen metabolite but not the acyl glucuronide.
- Author
-
Thomson P, Fragkas N, Kafu LM, Aithal GP, Lucena MI, Terracciano L, Meng X, Pirmohamed M, Brees D, Kullak-Ublick GA, Odermatt A, Hammond T, Kammüller M, and Naisbitt DJ
- Subjects
- Humans, Glucuronides metabolism, CD8-Positive T-Lymphocytes, Leukocytes, Mononuclear metabolism, Anti-Inflammatory Agents, Non-Steroidal, Ibuprofen, Oxidative Stress, Lymphocyte Activation, Naproxen adverse effects, Naproxen metabolism, Chemical and Drug Induced Liver Injury, Chronic
- Abstract
Background: Exposure to nonsteroidal anti-inflammatory drugs (NSAIDs) such as ibuprofen (IBU) and naproxen (NAP) is associated with idiosyncratic drug-induced liver injury (DILI). Carboxylate bioactivation into reactive metabolites (e.g., acyl glucuronides, AG) and resulting T-cell activation is hypothesized as causal for this adverse event. However, conclusive evidence supporting this is lacking., Methods: In this work, we identify CD4
+ and CD8+ T-cell hepatic infiltration in a biopsy from an IBU DILI patient. Lymphocyte transformation test and IFN-γ ELIspot, conducted on peripheral blood mononuclear cells (PBMCs) of patients with NAP-DILI, were used to explore drug-specific T-cell activation. T-cell clones (TCC) were generated and tested for drug specificity, phenotype/function, and pathways of T-cell activation. Cells were exposed to NAP, its oxidative metabolite 6-O-desmethyl NAP (DM-NAP), its AG or synthesized NAP-AG human-serum albumin adducts (NAP-AG adduct)., Results: CD4+ and CD8+ T-cells from patients expressing a range of different Vβ receptors were stimulated to proliferate and secrete IFN-γ and IL-22 when exposed to DM-NAP, but not NAP, NAP-AG or the NAP-AG adduct. Activation of the CD4+ TCC was HLA-DQ-restricted and dependent on antigen presenting cells (APC); most TCC were activated with DM-NAP-pulsed APC, while fixation of APC blocked the T-cell response. Cross-reactivity was not observed with structurally-related drugs., Conclusion: Our results confirm hepatic T-cell infiltrations in NSAID-induced DILI, and show a T-cell memory response toward DM-NAP indicating an immune-mediated basis for the adverse event. Whilst bioactivation at the carboxylate group is widely hypothesized to be pathogenic for NSAID associated DILI, we found no evidence of this with NAP., (© 2023 The Authors. Allergy published by European Academy of Allergy and Clinical Immunology and John Wiley & Sons Ltd.)- Published
- 2024
- Full Text
- View/download PDF
27. Study design for development of novel safety biomarkers of drug-induced liver injury by the translational safety biomarker pipeline (TransBioLine) consortium: a study protocol for a nested case-control study.
- Author
-
Grove JI, Stephens C, Lucena MI, Andrade RJ, Weber S, Gerbes A, Bjornsson ES, Stirnimann G, Daly AK, Hackl M, Khamina-Kotisch K, Marin JJG, Monte MJ, Paciga SA, Lingaya M, Forootan SS, Goldring CEP, Poetz O, Lombaard R, Stege A, Bjorrnsson HK, Robles-Diaz M, Li D, Tran TDB, Ramaiah SK, Samodelov SL, Kullak-Ublick GA, and Aithal GP
- Abstract
A lack of biomarkers that detect drug-induced liver injury (DILI) accurately continues to hinder early- and late-stage drug development and remains a challenge in clinical practice. The Innovative Medicines Initiative's TransBioLine consortium comprising academic and industry partners is developing a prospective repository of deeply phenotyped cases and controls with biological samples during liver injury progression to facilitate biomarker discovery, evaluation, validation and qualification.In a nested case-control design, patients who meet one of these criteria, alanine transaminase (ALT) ≥ 5 × the upper limit of normal (ULN), alkaline phosphatase ≥ 2 × ULN or ALT ≥ 3 ULN with total bilirubin > 2 × ULN, are enrolled. After completed clinical investigations, Roussel Uclaf Causality Assessment and expert panel review are used to adjudicate episodes as DILI or alternative liver diseases (acute non-DILI controls). Two blood samples are taken: at recruitment and follow-up. Sample size is as follows: 300 cases of DILI and 130 acute non-DILI controls. Additional cross-sectional cohorts (1 visit) are as follows: Healthy volunteers (n = 120), controls with chronic alcohol-related or non-alcoholic fatty liver disease (n = 100 each) and patients with psoriasis or rheumatoid arthritis (n = 100, 50 treated with methotrexate) are enrolled. Candidate biomarkers prioritised for evaluation include osteopontin, glutamate dehydrogenase, cytokeratin-18 (full length and caspase cleaved), macrophage-colony-stimulating factor 1 receptor and high mobility group protein B1 as well as bile acids, sphingolipids and microRNAs. The TransBioLine project is enabling biomarker discovery and validation that could improve detection, diagnostic accuracy and prognostication of DILI in premarketing clinical trials and for clinical healthcare application., (© 2023. BioMed Central Ltd., part of Springer Nature.)
- Published
- 2023
- Full Text
- View/download PDF
28. Nomenclature, diagnosis and management of drug-induced autoimmune-like hepatitis (DI-ALH): An expert opinion meeting report.
- Author
-
Andrade RJ, Aithal GP, de Boer YS, Liberal R, Gerbes A, Regev A, Terziroli Beretta-Piccoli B, Schramm C, Kleiner DE, De Martin E, Kullak-Ublick GA, Stirnimann G, Devarbhavi H, Vierling JM, Manns MP, Sebode M, Londoño MC, Avigan M, Robles-Diaz M, García-Cortes M, Atallah E, Heneghan M, Chalasani N, Trivedi PJ, Hayashi PH, Taubert R, Fontana RJ, Weber S, Oo YH, Zen Y, Licata A, Lucena MI, Mieli-Vergani G, Vergani D, and Björnsson ES
- Subjects
- Humans, Expert Testimony, Nitrofurantoin adverse effects, Congresses as Topic, Chemical and Drug Induced Liver Injury diagnosis, Chemical and Drug Induced Liver Injury etiology, Chemical and Drug Induced Liver Injury therapy, Hepatitis, Autoimmune diagnosis, Hepatitis, Autoimmune drug therapy, Hepatitis, Autoimmune etiology
- Abstract
Drug-induced liver injury (DILI) can mimic almost all other liver disorders. A phenotype increasingly ascribed to drugs is autoimmune-like hepatitis (ALH). This article summarises the major topics discussed at a joint International Conference held between the Drug-Induced Liver Injury consortium and the International Autoimmune Hepatitis Group. DI-ALH is a liver injury with laboratory and/or histological features that may be indistinguishable from those of autoimmune hepatitis (AIH). Previous studies have revealed that patients with DI-ALH and those with idiopathic AIH have very similar clinical, biochemical, immunological and histological features. Differentiating DI-ALH from AIH is important as patients with DI-ALH rarely require long-term immunosuppression and the condition often resolves spontaneously after withdrawal of the implicated drug, whereas patients with AIH mostly require long-term immunosuppression. Therefore, revision of the diagnosis on long-term follow-up may be necessary in some cases. More than 40 different drugs including nitrofurantoin, methyldopa, hydralazine, minocycline, infliximab, herbal and dietary supplements (such as Khat and Tinospora cordifolia) have been implicated in DI-ALH. Understanding of DI-ALH is limited by the lack of specific markers of the disease that could allow for a precise diagnosis, while there is similarly no single feature which is diagnostic of AIH. We propose a management algorithm for patients with liver injury and an autoimmune phenotype. There is an urgent need to prospectively evaluate patients with DI-ALH systematically to enable definitive characterisation of this condition., (Copyright © 2023 The Author(s). Published by Elsevier B.V. All rights reserved.)
- Published
- 2023
- Full Text
- View/download PDF
29. Astragaloside IV alleviates 1-deoxysphinganine-induced mitochondrial dysfunction during the progression of chronic kidney disease through p62-Nrf2 antioxidant pathway.
- Author
-
Gui T, Chen Q, Li J, Lu K, Li C, Xu B, Chen Y, Men J, Kullak-Ublick GA, Wang W, and Gai Z
- Abstract
Introduction: Chronic kidney disease (CKD) can lead to significant elevation of 1-deoxysphingolipids (1-deoxySL). The increase of 1-deoxySL in turn can result in mitochondrial damage and oxidative stress, which can cause further progression of CKD. Methods: This study assessed the therapeutic effect of Astragaloside IV (AST) against 1-deoxySL-induced cytotoxicity in vitro and in rats with CKD. HK-2 cells were exposed to 1-deoxysphinganine (doxSA) or doxSA + AST. doxSA-induced mitochondrial dysfunction and oxidative stress were evaluated by immunostaining, real-time PCR, oxidative stress sensor, and transmission electron microscopy. The potential effects of AST on kidney damage were evaluated in a rat 5/6 nephrectomy (5/6 Nx) model of CKD. Results: The findings of in vitro experiments showed that doxSA induced mitochondrial damage, oxidative stress, and apoptosis. AST markedly reduced the level of mitochondrial reactive oxygen species, lowered apoptosis, and improved mitochondrial function. In addition, exposure to AST significantly induced the phosphorylation of p62 and the nuclear translocation of Nrf2 as well as its downstream anti-oxidant genes. p62 knock-down fully abolished Nrf2 nuclear translocation in cells after AST treatment. However, p62 knock-down did not affect TBHQ-induced Nrf2 nuclear translocation, indicating that AST can ameliorate doxSA-induced oxidative stress through modulation of p62 phosphorylation and Nrf2 nuclear translocation. Conclusion: The findings indicate that AST can activate Nrf2 antioxidant pathway in a p62 dependent manner. The anti-oxidative stress effect and the further mitochondrial protective effect of AST represent a promising therapeutic strategy for the progression of CKD., Competing Interests: GK-U was employed by the company Novartis Pharma. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest., (Copyright © 2023 Gui, Chen, Li, Lu, Li, Xu, Chen, Men, Kullak-Ublick, Wang and Gai.)
- Published
- 2023
- Full Text
- View/download PDF
30. Characterization of ligand-induced thermal stability of the human organic cation transporter 2 (OCT2).
- Author
-
Maane M, Xiu F, Bellstedt P, Kullak-Ublick GA, and Visentin M
- Abstract
Introduction: The human organic cation transporter 2 (OCT2) is involved in the transport of endogenous quaternary amines and positively charged drugs across the basolateral membrane of proximal tubular cells. In the absence of a structure, the progress in unraveling the molecular basis of OCT2 substrate specificity is hampered by the unique complexity of OCT2 binding pocket, which seemingly contains multiple allosteric binding sites for different substrates. Here, we used the thermal shift assay (TSA) to better understand the thermodynamics governing OCT2 binding to different ligands. Methods: Molecular modelling and in silico docking of different ligands revealed two distinct binding sites at OCT2 outer part of the cleft. The predicted interactions were assessed by cis -inhibition assay using [
3 H]1-methyl-4-phenylpyridinium ([3 H]MPP+ ) as a model substrate, or by measuring the uptake of radiolabeled ligands in intact cells. Crude membranes from HEK293 cells harboring human OCT2 (OCT2-HEK293) were solubilized in n-Dodecyl-β-D-Maltopyranoside (DDM), incubated with the ligand, heated over a temperature gradient, and then pelleted to remove heat-induced aggregates. The OCT2 in the supernatant was detected by western blot. Results: Among the compounds tested, cis -inhibition and TSA assays showed partly overlapping results. Gentamicin and methotrexate (MTX) did not inhibit [3 H]MPP+ uptake but significantly increased the thermal stabilization of OCT2. Conversely, amiloride completely inhibited [3 H]MPP+ uptake but did not affect OCT2 thermal stabilization. [3 H]MTX intracellular level was significantly higher in OCT2-HEK293 cells than in wild type cells. The magnitude of the thermal shift (ΔTm ) did not provide information on the binding. Ligands with similar affinity showed markedly different ΔTm , indicating different enthalpic and entropic contributions for similar binding affinities. The ΔTm positively correlated with ligand molecular weight/chemical complexity, which typically has high entropic costs, suggesting that large ΔTm reflect a larger displacement of bound water molecules. Discussion: In conclusion, TSA might represent a viable approach to expand our knowledge on OCT2 binding descriptors., Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest., (Copyright © 2023 Maane, Xiu, Bellstedt, Kullak-Ublick and Visentin.)- Published
- 2023
- Full Text
- View/download PDF
31. Novel insights into bile acid detoxification via CYP, UGT and SULT enzymes.
- Author
-
Kastrinou Lampou V, Poller B, Huth F, Fischer A, Kullak-Ublick GA, Arand M, Schadt HS, and Camenisch G
- Subjects
- Humans, Cytochrome P-450 CYP3A metabolism, Microsomes, Liver metabolism, Homeostasis, Liver metabolism, Glucuronosyltransferase metabolism, Bile Acids and Salts metabolism, Cholestasis chemically induced, Cholestasis metabolism
- Abstract
Bile acid (BA) homeostasis is a complex and precisely regulated process to prevent impaired BA flow and the development of cholestasis. Several reactions, namely hydroxylation, glucuronidation and sulfation are involved in BA detoxification. In the present study, we employed a comprehensive approach to identify the key enzymes involved in BA metabolism using human recombinant enzymes, human liver microsomes (HLM) and human liver cytosol (HLC). We showed that CYP3A4 was a crucial step for the metabolism of several BAs and their taurine and glycine conjugated forms and quantitatively described their metabolites. Glucuronidation and sulfation were also identified as important drivers of the BA detoxification process in humans. Moreover, lithocholic acid (LCA), the most hydrophobic BA with the highest toxicity potential, was a substrate for all investigated processes, demonstrating the importance of hepatic metabolism for its clearance. Collectively, this study identified CYP3A4, UGT1A3, UGT2B7 and SULT2A1 as the major contributing (metabolic) processes in the BA detoxification network. Inhibition of these enzymes by drug candidates is therefore considered as a critical mechanism in the manifestation of drug-induced cholestasis in humans and should be addressed during the pre-clinical development., Competing Interests: Declaration of Competing Interest None of the authors has any conflict of interest to this study to declare., (Copyright © 2022 Elsevier Ltd. All rights reserved.)
- Published
- 2023
- Full Text
- View/download PDF
32. Plasma Sphingoid Base Profiles of Patients Diagnosed with Intrinsic or Idiosyncratic Drug-induced Liver Injury.
- Author
-
Gai Z, Samodelov SL, Alecu I, Hornemann T, Grove JI, Aithal GP, Visentin M, and Kullak-Ublick GA
- Subjects
- Humans, Sphingolipids metabolism, Liver metabolism, Chemical and Drug Induced Liver Injury diagnosis, Chemical and Drug Induced Liver Injury etiology, Drug-Related Side Effects and Adverse Reactions
- Abstract
Sphingolipids are exceptionally diverse, comprising hundreds of unique species. The bulk of circulating sphingolipids are synthesized in the liver, thereby plasma sphingolipid profiles represent reliable surrogates of hepatic sphingolipid metabolism and content. As changes in plasma sphingolipid content have been associated to exposure to drugs inducing hepatotoxicity both in vitro and in rodents, in the present study the translatability of the preclinical data was assessed by analyzing the plasma of patients with suspected drug-induced liver injury (DILI) and control subjects. DILI patients, whether intrinsic or idiosyncratic cases, had no alterations in total sphingoid base levels and profile composition compared to controls, whereby cardiovascular disease (CVD) was a confounding factor. Upon exclusion of CVD individuals, elevation of 1-deoxysphingosine (1-deoxySO) in the DILI group emerged. Notably, 1-deoxySO values did not correlate with ALT values. While 1-deoxySO was elevated in all DILI cases, only intrinsic DILI cases concomitantly displayed reduction of select shorter chain sphingoid bases. Significant perturbation of the sphingolipid metabolism observed in this small exploratory clinical study is discussed and put into context, in the consideration that sphingolipids might contribute to the onset and progression of DILI, and that circulating sphingoid bases may function as mechanistic markers to study DILI pathophysiology.
- Published
- 2023
- Full Text
- View/download PDF
33. The Farnesoid X Receptor as a Master Regulator of Hepatotoxicity.
- Author
-
Rausch M, Samodelov SL, Visentin M, and Kullak-Ublick GA
- Subjects
- Humans, Receptors, Cytoplasmic and Nuclear, Homeostasis, Lipids, Bile Acids and Salts, Chemical and Drug Induced Liver Injury
- Abstract
The nuclear receptor farnesoid X receptor (FXR, NR1H4) is a bile acid (BA) sensor that links the enterohepatic circuit that regulates BA metabolism and elimination to systemic lipid homeostasis. Furthermore, FXR represents a real guardian of the hepatic function, preserving, in a multifactorial fashion, the integrity and function of hepatocytes from chronic and acute insults. This review summarizes how FXR modulates the expression of pathway-specific as well as polyspecific transporters and enzymes, thereby acting at the interface of BA, lipid and drug metabolism, and influencing the onset and progression of hepatotoxicity of varying etiopathogeneses. Furthermore, this review article provides an overview of the advances and the clinical development of FXR agonists in the treatment of liver diseases.
- Published
- 2022
- Full Text
- View/download PDF
34. Corrigendum to "The role of cholesterol recognition (CARC/CRAC) mirror codes in the allosterism of the human organic cation transporter 2 (OCT2, SLC22A2)" [Biochem. Pharmacol. 194 (2021) 114840].
- Author
-
Sutter ML, Console L, Fahner AF, Samodelov SL, Gai Z, Ciarimboli G, Indiveri C, Kullak-Ublick GA, and Visentin M
- Published
- 2022
- Full Text
- View/download PDF
35. The Role of NF-kB in the Downregulation of Organic Cation Transporter 2 Expression and Renal Cation Secretion in Kidney Disease.
- Author
-
Han C, Zheng J, Wang F, Lu Q, Chen Q, Hu A, Visentin M, Kullak-Ublick GA, Gai Z, and Chu L
- Abstract
Organic cation transporter 2 (OCT2), encoded by the SLC22A2 gene, is the main cation transporter on the basolateral membrane of proximal tubular cells. OCT2 facilitates the entry step of the vectorial transport of most cations from the peritubular space into the urine. OCT2 downregulation in kidney disease models is apparent, yet not clear from a mechanistic vantage point. The aim of this study was to explore the role of inflammation, a common thread in kidney disease, and NF-kB in OCT2 modulation and tubular secretion. Among the OCTs, OCT2 was found consistently downregulated in the kidney of rats with chronic kidney disease (CKD) or acute kidney injury (AKI) and in patients diagnosed with CKD, and it was associated with the upregulation of TNFα renal expression. Exposure to TNFα reduced the expression and function of OCT2 in primary renal proximal tubule epithelial cells (RPTEC). Silencing or pharmacological inhibition of NF-kB rescued the expression of OCT2 in the presence of TNFα, indicating that OCT2 repression was NF-kB-dependent. In silico prediction coupled to gene reporter assay demonstrated the presence of at least one functional NF-kB cis -element upstream the transcription starting site of the SLC22A2 gene. Acute inflammation triggered by lipopolysaccharide injection induced TNFα expression and the downregulation of OCT2 in rat kidney. The inflammation did reduce the active secretion of the cation Rhodamine 123, with no impairment of the glomerular filtration. In conclusion, the NF-kB pathway plays a major role in the transcriptional regulation of OCT2 and, in turn, in the overall renal secretory capacity., Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest., (Copyright © 2022 Han, Zheng, Wang, Lu, Chen, Hu, Visentin, Kullak-Ublick, Gai and Chu.)
- Published
- 2022
- Full Text
- View/download PDF
36. Hepatic safety and tolerability of cipargamin (KAE609), in adult patients with Plasmodium falciparum malaria: a randomized, phase II, controlled, dose-escalation trial in sub-Saharan Africa.
- Author
-
Ndayisaba G, Yeka A, Asante KP, Grobusch MP, Karita E, Mugerwa H, Asiimwe S, Oduro A, Fofana B, Doumbia S, Jain JP, Barsainya S, Kullak-Ublick GA, Su G, Schmitt EK, Csermak K, Gandhi P, and Hughes D
- Subjects
- Adult, Female, Humans, Male, Middle Aged, Young Adult, Dose-Response Relationship, Drug, Gabon, Ghana, Mali, Rwanda, Uganda, Antimalarials adverse effects, Antimalarials therapeutic use, Indoles adverse effects, Indoles therapeutic use, Liver drug effects, Spiro Compounds adverse effects, Spiro Compounds therapeutic use, Malaria, Falciparum drug therapy
- Abstract
Background: The novel anti-malarial cipargamin (KAE609) has potent, rapid activity against Plasmodium falciparum. Transient asymptomatic liver function test elevations were previously observed in cipargamin-treated subjects in two trials: one in malaria patients in Asia and one in volunteers with experimentally induced malaria. In this study, the hepatic safety of cipargamin given as single doses of 10 to 150 mg and 10 to 50 mg once daily for 3 days was assessed. Efficacy results, frequency of treatment-emerging mutations in the atp4 gene and pharmacokinetics have been published elsewhere. Further, the R561H mutation in the k13 gene, which confers artemisinin-resistance, was associated with delayed parasite clearance following treatment with artemether-lumefantrine in Rwanda in this study. This was also the first study with cipargamin to be conducted in patients in sub-Saharan Africa., Methods: This was a Phase II, multicentre, randomized, open-label, dose-escalation trial in adults with uncomplicated falciparum malaria in five sub-Saharan countries, using artemether-lumefantrine as control. The primary endpoint was ≥ 2 Common Terminology Criteria for Adverse Events (CTCAE) Grade increase from baseline in alanine aminotransferase (ALT) or aspartate transaminase (AST) during the 4-week trial., Results: Overall, 2/135 patients treated with cipargamin had ≥ 2 CTCAE Grade increases from baseline in ALT or AST compared to 2/51 artemether-lumefantrine patients, with no significant difference between any cipargamin treatment group and the control group. Cipargamin exposure was comparable to or higher than those in previous studies. Hepatic adverse events and general safety and tolerability were similar for all cipargamin doses and artemether-lumefantrine. Cipargamin was well tolerated with no safety concerns., Conclusions: This active-controlled, dose escalation study was a detailed assessment of the hepatic safety of cipargamin, across a wide range of doses, in patients with uncomplicated falciparum malaria. Comparison with previous cipargamin trials requires caution as no clear conclusion can be drawn as to whether hepatic safety and potential immunity to malaria would differ with ethnicity, patient age and or geography. Previous concerns regarding hepatic safety may have been confounded by factors including malaria itself, whether natural or experimental infection, and should not limit the further development of cipargamin. Trial registration ClinicalTrials.gov number: NCT03334747 (7 Nov 2017), other study ID CKAE609A2202., (© 2021. The Author(s).)
- Published
- 2021
- Full Text
- View/download PDF
37. The role of cholesterol recognition (CARC/CRAC) mirror codes in the allosterism of the human organic cation transporter 2 (OCT2, SLC22A2).
- Author
-
Sutter ML, Console L, Fahner AF, Samodelov SL, Gai Z, Ciarimboli G, Indiveri C, Kullak-Ublick GA, and Visentin M
- Subjects
- Allosteric Regulation physiology, Amino Acid Sequence, Cholesterol genetics, HEK293 Cells, Humans, Organic Cation Transporter 2 chemistry, Organic Cation Transporter 2 genetics, Protein Structure, Secondary, Cholesterol metabolism, Organic Cation Transporter 2 metabolism
- Abstract
The human organic cation transporter 2 (OCT2) is a multispecific transporter with cholesterol-dependent allosteric features. The present work elucidates the role of evolutionarily conserved cholesterol recognition/interaction amino acid consensus sequences (CRAC and CARC) in the allosteric binding to 1-methyl-4-phenylpyridinium (MPP
+ ) in human embryonic kidney 293 cells stably or transiently expressing OCT2. Molecular blind simulations docked two mirroring cholesterol molecules in the 5th putative transmembrane domain, where a CARC and a CRAC sequence lie. The impact of the conserved amino acids that may constitute the CARC/CRAC mirror code was studied by alanine-scanning mutagenesis. At a saturating extracellular concentration of substrate, at which the impact of cholesterol depletion is maximal, five mutants transported MPP+ at a significantly lower rate than the wild-type OCT2 (WT), resembling the behavior of the WT upon cholesterol depletion. MPP+ influx rate as a function of the extracellular concentration of substrate was measured for the mutants R234A, R235A, L252A and R263A. R234A kinetic behavior was similar to that of the WT, whereas R235A, L252A and R263A activity shifted from allosteric to one-binding site kinetics, very much like the WT upon cholesterol depletion. The impact of cholesterol on protein thermal stability was assessed for WT, R234A and R263A. While the thermal stability of WT and R234A was improved by the supplementation with cholesterol, R263A was not sensitive to the presence of cholesterol. To conclude, the disruption of the CARC/CRAC mirror code in the 5th putative transmembrane domain is sufficient to abolish the allosteric interaction between OCT2 and MPP+ ., (Copyright © 2021. Published by Elsevier Inc.)- Published
- 2021
- Full Text
- View/download PDF
38. Nukleäre Rezeptoren beim hepatischen und intestinalen Medikamententransport.
- Author
-
Kullak-Ublick GA
- Subjects
- Biological Transport, Liver metabolism, Pharmaceutical Preparations metabolism, Receptors, Cytoplasmic and Nuclear metabolism
- Abstract
Competing Interests: Aktien bei Novartis.
- Published
- 2021
- Full Text
- View/download PDF
39. Biomarkers of idiosyncratic drug-induced liver injury (DILI) - a systematic review.
- Author
-
Atallah E, Freixo C, Alvarez-Alvarez I, Cubero FJ, Gerbes AL, Kullak-Ublick GA, and Aithal GP
- Subjects
- Biomarkers, Humans, Liver, Prospective Studies, Risk Factors, Chemical and Drug Induced Liver Injury diagnosis, Chemical and Drug Induced Liver Injury etiology, Drug-Related Side Effects and Adverse Reactions diagnosis
- Abstract
Introduction: Idiosyncratic drug-induced liver injury (DILI) is an unpredictable event, and there are no specific biomarkers that can distinguish DILI from alternative explanations or predict its clinical outcomes., Areas Covered: This systematic review summarizes the available evidence for all biomarkers proposed to have a role in the diagnosis or prognosis of DILI. Following a comprehensive search, we included all types of studies in humans. We included DILI cases based on any threshold criteria but excluded intrinsic DILI, commonly caused by paracetamol overdose. We classified studies into diagnostic and prognostic categories and assessed their methodological quality. After reviewing the literature, 14 studies were eligible., Expert Opinion: Diagnostic studies were heterogeneous with regard to the study population and outcomes measured. Prognostic models were developed by integrating novel biomarkers, risk scores, and traditional biomarkers, which increased their prognostic ability to predict death or transplantation by 6 months. This systematic review highlights the case of need for non-genetic biomarkers that distinguish DILI from acute liver injury related to alternative etiology. Biomarkers with the potential to identify serious adverse outcomes from acute DILI should be validated in independent prospective cohorts with a substantial number of cases.
- Published
- 2021
- Full Text
- View/download PDF
40. The Role of the Carnitine/Organic Cation Transporter Novel 2 in the Clinical Outcome of Patients With Locally Advanced Esophageal Carcinoma Treated With Oxaliplatin.
- Author
-
Sun D, Chen Q, Gai Z, Zhang F, Yang X, Hu W, Chen C, Yang G, Hörmann S, Kullak-Ublick GA, and Visentin M
- Abstract
Esophageal cancer is the ninth most common malignancy worldwide, ranking sixth in mortality. Platinum-based chemotherapy is commonly used for treating locally advanced esophageal cancer, yet it is ineffective in a large portion of patients. There is a need for reliable molecular markers with direct clinical application for a prospective selection of patients who can benefit from chemotherapy and patients in whom toxicity is likely to outweigh the benefit. The cytotoxic activity of platinum derivatives largely depends on the uptake and accumulation into cells, primarily by organic cation transporters (OCTs). The aim of the study was to investigate the impact of OCT expression on the clinical outcome of patients with esophageal cancer treated with oxaliplatin. Twenty patients with esophageal squamous cell carcinoma (SCC) were prospectively enrolled and surgical specimens used for screening OCT expression level by western blotting and/or immunostaining, and for culture of cancer cells. Sixty-seven patients with SCC who received oxaliplatin and for whom follow-up was available were retrospectively assessed for organic cation/carnitine transporter 2 (OCTN2) expression by real time RT-PCR and immunostaining. OCTN2 staining was also performed in 22 esophageal adenocarcinomas. OCTN2 function in patient-derived cancer cells was evaluated by assessing L-carnitine uptake and sensitivity to oxaliplatin. The impact of OCTN2 on oxaliplatin activity was also assessed in HEK293 cells overexpressing OCTN2. OCTN2 expression was higher in tumor than in normal tissues. In patient-derived cancer cells and HEK293 cells, the expression of OCTN2 sensitized to oxaliplatin. Patients treated with oxaliplatin who had high OCTN2 level in the tumor tissue had a reduced risk of recurrence and a longer survival time than those with low expression of OCTN2 in tumor tissue. In conclusion, OCTN2 is expressed in esophageal cancer and it is likely to contribute to the accumulation and cytotoxic activity of oxaliplatin in patients with esophageal carcinoma treated with oxaliplatin., Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest., (Copyright © 2021 Sun, Chen, Gai, Zhang, Yang, Hu, Chen, Yang, Hörmann, Kullak-Ublick and Visentin.)
- Published
- 2021
- Full Text
- View/download PDF
41. Drug-induced liver injury in Switzerland: an analysis of drug-related hepatic disorders in the WHO pharmacovigilance database VigiBase from 2010 to 2020.
- Author
-
Ortland I, Mirjalili M, Kullak-Ublick GA, and Peymani P
- Subjects
- Adverse Drug Reaction Reporting Systems, Databases, Factual, Female, Humans, Male, Middle Aged, Pharmacovigilance, Retrospective Studies, Switzerland epidemiology, World Health Organization, Chemical and Drug Induced Liver Injury epidemiology, Chemical and Drug Induced Liver Injury etiology, Drug-Related Side Effects and Adverse Reactions epidemiology, Pharmaceutical Preparations
- Abstract
Aims of the Study: Our aim was to explore drug-induced liver injury (DILI) in Switzerland using the real-world data of the global pharmacovigilance database VigiBaseÔ, with a special focus on the new drug class of checkpoint inhibitors. This is the first study investigating drug-related hepatic disorders in Switzerland in a global pharmacovigilance database., Methods: This was a retrospective study analysing the ICSRs (individual case safety reports) of the global pharmacovigilance database VigiBaseÔ. We explored all ICSRs submitted in Switzerland within the last 10 years (1 July 2010 to 30 June 2020). For data extraction, the standardised MedDRA query (SMQ) “narrow drug-related hepatic disorders – severe events only” was applied. The ICSRs, drug-reaction pairs and adverse drug reactions were analysed descriptively, including a special focus on checkpoint inhibitors. For comparing the hepatic adverse drug reactions of pembrolizumab, nivolumab and ipilimumab, the reporting odds ratios (RORs) were calculated in a disproportionality analysis., Results: In total, 2042 ICSRs could be investigated, comprising 10,646 drugs and 6436 adverse drug reactions. Gender was equally distributed between male and female. Patients were on average 57 years old. The mortality rate was high, with fatal adverse reactions in over 10% of cases. On average, patients used five drugs including two suspected drugs. Paracetamol, amoxicillin/clavulanic acid, esomeprazole and atorvastatin ranked among the most frequently suspected drugs for severe drug-related hepatic disorders. However, VigibaseÔ data are not appropriate for judging causality and these results should be interpreted with caution owing to the possible influences of comedication or comorbidity. An average of three adverse drug reactions per ICSR were reported, most frequently including hepatocellular injury, cholestatic liver injury, and liver injury. For checkpoint inhibitors, hepatitis was the most frequently reported hepatic adverse drug reaction. In comparison with nivolumab and ipilimumab, pembrolizumab had a significantly higher ROR for hepatitis (2.41, p = 0.016), but also a lower ROR for autoimmune hepatitis (0.11, p = 0.009)., Conclusion: Our findings highlight the importance for healthcare providers in Switzerland to pay special attention to possible drug-induced liver injuries because of their high mortality rate. The analysis of real-world data confirms the previous assumption that hepatitis is the most frequent hepatic adverse event for checkpoint inhibitors. Further clinical studies are warranted to directly compare hepatic adverse drug reactions to different checkpoint inhibitors.
- Published
- 2021
- Full Text
- View/download PDF
42. Evaluating the Sensitivity and Specificity of Promising Circulating Biomarkers to Diagnose Liver Injury in Humans.
- Author
-
Llewellyn HP, Vaidya VS, Wang Z, Peng Q, Hyde C, Potter D, Wang J, Zong Q, Arat S, Martin M, Masek-Hammerman K, Warner R, Johnson K, Kullak-Ublick GA, Aithal GP, Dear JW, and Ramaiah SK
- Subjects
- Acetaminophen, Alanine Transaminase, Animals, Biomarkers, Humans, Liver, Rats, Chemical and Drug Induced Liver Injury diagnosis, MicroRNAs
- Abstract
Early diagnosis of drug-induced liver injury (DILI) continues to be a major hurdle during drug development and postmarketing. The objective of this study was to evaluate the diagnostic performance of promising biomarkers of liver injury-glutamate dehydrogenase (GLDH), cytokeratin-18 (K18), caspase-cleaved K18 (ccK18), osteopontin (OPN), macrophage colony-stimulating factor (MCSF), MCSF receptor (MCSFR), and microRNA-122 (miR-122) in comparison to the traditional biomarker alanine aminotransferase (ALT). Biomarkers were evaluated individually and as a multivariate model in a cohort of acetaminophen overdose (n = 175) subjects and were further tested in cohorts of healthy adults (n = 135), patients with liver damage from various causes (n = 104), and patients with damage to the muscle (n = 74), kidney (n = 40), gastrointestinal tract (n = 37), and pancreas (n = 34). In the acetaminophen cohort, a multivariate model with GLDH, K18, and miR-122 was able to detect DILI more accurately than individual biomarkers alone. Furthermore, the three-biomarker model could accurately predict patients with liver injury compared with healthy volunteers or patients with damage to muscle, pancreas, gastrointestinal tract, and kidney. Expression of K18, GLDH, and miR-122 was evaluated using a database of transcriptomic profiles across multiple tissues/organs in humans and rats. K18 mRNA (Krt18) and MiR-122 were highly expressed in liver whereas GLDH mRNA (Glud1) was widely expressed. We performed a comprehensive, comparative performance assessment of 7 promising biomarkers and demonstrated that a 3-biomarker multivariate model can accurately detect liver injury., (© The Author(s) 2021. Published by Oxford University Press on behalf of the Society of Toxicology. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.)
- Published
- 2021
- Full Text
- View/download PDF
43. Thermoplasmonic-Assisted Cyclic Cleavage Amplification for Self-Validating Plasmonic Detection of SARS-CoV-2.
- Author
-
Qiu G, Gai Z, Saleh L, Tang J, Gui T, Kullak-Ublick GA, and Wang J
- Subjects
- Female, Humans, Nucleic Acid Amplification Techniques, RNA, Viral, Sensitivity and Specificity, COVID-19, SARS-CoV-2
- Abstract
The coronavirus disease 2019 (COVID-19) has penetrated every populated patch of the globe and sows destruction in our daily life. Reliable and sensitive virus sensing systems are therefore of vital importance for timely infection detection and transmission prevention. Here we present a thermoplasmonic-assisted dual-mode transducing (TP-DMT) concept, where an amplification-free-based direct viral RNA detection and an amplification-based cyclic fluorescence probe cleavage (CFPC) detection collaborated to provide a sensitive and self-validating plasmonic nanoplatform for quantifying trace amounts of SARS-CoV-2 within 30 min. In the CFPC detection, endonuclease IV recognized the synthetic abasic site and cleaved the fluorescent probes in the hybridized duplex. The nanoscale thermoplasmonic heating dehybridized the shortened fluorescent probes and facilitated the cyclical binding-cleavage-dissociation (BCD) process, which could deliver a highly sensitive amplification-based response. This TP-DMT approach was successfully validated by testing clinical COVID-19 patient samples, which indicated its potential applications in fast clinical infection screening and real-time environmental monitoring.
- Published
- 2021
- Full Text
- View/download PDF
44. Oxidative stress increases 1-deoxysphingolipid levels in chronic kidney disease.
- Author
-
Gui T, Li Y, Zhang S, Alecu I, Chen Q, Zhao Y, Hornemann T, Kullak-Ublick GA, and Gai Z
- Subjects
- Animals, Humans, Kidney metabolism, Oxidative Stress, Rats, Rats, Sprague-Dawley, Sphingolipids metabolism, Renal Insufficiency, Chronic metabolism
- Abstract
Chronic kidney disease (CKD) leads to deep changes in lipid metabolism and obvious dyslipidemia. The dysregulation of lipid metabolism in turn results in CKD progression and the complications of cardiovascular diseases. To obtain a profound insight into the associated dyslipidemia in CKD, we performed lipidomic analysis to measure lipid metabolites in the serum from a rat 5/6 nephrectomy (5/6 Nx) model of CKD as well as in the serum from CKD patients. HK-2 cells were also used to examine oxidative stress-induced sphingolipid changes. Totally 182 lipid species were identified in 5/6 Nx rats. We found glycerolipids, total free fatty acids, and sphingolipids levels were significantly upregulated in 5/6 Nx rats. The atypical sphingolipids, 1-deoxysphingolipids, were significantly altered in both CKD animals and human CKD patients. The levels of 1-deoxysphingolipids directly relevant to the level of oxidative stress in vivo and in vitro. These results demonstrate that 1-deoxysphingolipid levels are increased in CKD and this increase directly correlates with increased kidney oxidative stress., (Copyright © 2021 The Authors. Published by Elsevier Inc. All rights reserved.)
- Published
- 2021
- Full Text
- View/download PDF
45. Cholesterol stimulates the cellular uptake of L-carnitine by the carnitine/organic cation transporter novel 2 (OCTN2).
- Author
-
Zhang L, Gui T, Console L, Scalise M, Indiveri C, Hausler S, Kullak-Ublick GA, Gai Z, and Visentin M
- Subjects
- Biological Transport, HEK293 Cells, Humans, Proteolipids metabolism, Carnitine metabolism, Cholesterol metabolism, Solute Carrier Family 22 Member 5 metabolism
- Abstract
The carnitine/organic cation transporter novel 2 (OCTN2) is responsible for the cellular uptake of carnitine in most tissues. Being a transmembrane protein OCTN2 must interact with the surrounding lipid microenvironment to function. Among the main lipid species that constitute eukaryotic cells, cholesterol has highly dynamic levels under a number of physiopathological conditions. This work describes how plasma membrane cholesterol modulates OCTN2 transport of L-carnitine in human embryonic kidney 293 cells overexpressing OCTN2 (OCTN2-HEK293) and in proteoliposomes harboring human OCTN2. We manipulated the cholesterol content of intact cells, assessed by thin layer chromatography, through short exposures to empty and/or cholesterol-saturated methyl-β-cyclodextrin (mβcd), whereas free cholesterol was used to enrich reconstituted proteoliposomes. We measured OCTN2 transport using [
3 H]L-carnitine, and expression levels and localization by surface biotinylation and Western blotting. A 20-min preincubation with mβcd reduced the cellular cholesterol content and inhibited L-carnitine influx by 50% in comparison with controls. Analogously, the insertion of cholesterol in OCTN2-proteoliposomes stimulated L-carnitine uptake in a dose-dependent manner. Carnitine uptake in cells incubated with empty mβcd and cholesterol-saturated mβcd to preserve the cholesterol content was comparable with controls, suggesting that the mβcd effect on OCTN2 was cholesterol dependent. Cholesterol stimulated L-carnitine influx in cells by markedly increasing the affinity for L-carnitine and in proteoliposomes by significantly enhancing the affinity for Na+ and, in turn, the L-carnitine maximal transport capacity. Because of the antilipogenic and antioxidant features of L-carnitine, the stimulatory effect of cholesterol on L-carnitine uptake might represent a novel protective effect against lipid-induced toxicity and oxidative stress., Competing Interests: Conflict of interest The authors declare no conflicts of interest in regards to this manuscript., (Copyright © 2020 The Authors. Published by Elsevier Inc. All rights reserved.)- Published
- 2021
- Full Text
- View/download PDF
46. Untargeted Metabolomics Reveals Anaerobic Glycolysis as a Novel Target of the Hepatotoxic Antidepressant Nefazodone.
- Author
-
Krajnc E, Visentin M, Gai Z, Stieger B, Samodelov SL, Häusler S, and Kullak-Ublick GA
- Subjects
- Adenosine Triphosphate metabolism, Anaerobiosis drug effects, Animals, Biological Transport drug effects, Cell Line, Glucose metabolism, Glycolysis drug effects, Humans, Mice, Antidepressive Agents adverse effects, Liver drug effects, Liver metabolism, Metabolomics, Piperazines adverse effects, Triazoles adverse effects
- Abstract
Mitochondrial damage is considered a hallmark of drug-induced liver injury (DILI). However, despite the common molecular etiology, the evolution of the injury is usually unpredictable, with some cases that are mild and reversible upon discontinuation of the treatment and others characterized by irreversible acute liver failure. This suggests that additional mechanisms of damage play a role in determining the progression of the initial insult. To uncover novel pathways potentially involved in DILI, we investigated in vitro the metabolic perturbations associated with nefazodone, an antidepressant associated with acute liver failure. Several pathways associated with ATP production, including gluconeogenesis, anaerobic glycolysis, and oxidative phosphorylation, were altered in human hepatocellular carcinoma-derived (Huh7) cells after 2-hour exposure to a 50 μM extracellular concentration of nefazodone. In the presence or absence of glucose, ATP production of Huh7 cells was glycolysis- and oxidative phosphorylation-dependent, respectively. In glucose-containing medium, nefazodone-induced ATP depletion from Huh7 cells was biphasic. Huh7 cells in glucose-free medium were more sensitive to nefazodone than those in glucose-containing medium, losing the biphasic inhibition. Nefazodone-induced ATP depletion in primary cultured mouse hepatocytes, mainly dependent on oxidative phosphorylation, was monophasic. At lower extracellular concentrations, nefazodone inhibited the oxygen consumption of Huh7 cells, whereas at higher extracellular concentrations, it also inhibited the extracellular acidification. ATP content was rescued by increasing the extracellular concentration of glucose. In conclusion, nefazodone has a dual inhibitory effect on mitochondrial-dependent and mitochondrial-independent ATP production. SIGNIFICANCE STATEMENT: Mitochondrial damage is a hallmark of drug-induced liver injury, yet other collateral alterations might contribute to the severity and evolution of the injury. Our in vitro study supports previous results arguing that a deficit in hepatic glucose metabolism, concomitant to the mitochondrial injury, might be cardinal in the prognosis of the initial insult to the liver. From a drug development standpoint, coupling anaerobic glycolysis and mitochondrial function assessment might increase the drug-induced liver injury preclinical screening performance., (Copyright © 2020 by The American Society for Pharmacology and Experimental Therapeutics.)
- Published
- 2020
- Full Text
- View/download PDF
47. Best practices for detection, assessment and management of suspected immune-mediated liver injury caused by immune checkpoint inhibitors during drug development.
- Author
-
Regev A, Avigan MI, Kiazand A, Vierling JM, Lewis JH, Omokaro SO, Di Bisceglie AM, Fontana RJ, Bonkovsky HL, Freston JW, Uetrecht JP, Miller ED, Pehlivanov ND, Haque SA, Harrison MJ, Kullak-Ublick GA, Li H, Patel NN, Patwardhan M, Price KD, Watkins PB, and Chalasani NP
- Subjects
- Animals, Disease Management, Drug Development, Humans, Immune Checkpoint Inhibitors therapeutic use, Liver Function Tests, Neoplasms complications, Neoplasms drug therapy, Chemical and Drug Induced Liver Injury diagnosis, Chemical and Drug Induced Liver Injury etiology, Disease Susceptibility, Immune Checkpoint Inhibitors adverse effects
- Abstract
Immune checkpoint inhibitors (ICIs) have shown significant efficacy in patients with various malignancies, however, they are associated with a wide range of immune-related toxicities affecting many organs, including the liver. Immune-mediated liver injury caused by checkpoint inhibitors (ILICI) is a distinctive form of drug induced liver injury (DILI), that differs from most DILI types in presumed underlying mechanism, incidence, and response to therapeutic interventions. Despite increased awareness of ILICI and other immune-related adverse effects of ICIs reflected by recent guidelines for their management in post marketing clinical practice, there is lack of uniform best practices to address ILICI risk during drug development. As efforts to develop safer and more effective ICIs for additional indications grow, and as combination therapies including ICIs are increasingly investigated, there is a growing need for consistent practices for ILICI in drug development. This publication summarizes current best practices to optimize the monitoring, diagnosis, assessment, and management of suspected ILICI in clinical trials using ICI as a single agent and in combination with other ICIs or other oncological agents. It is one of several publications developed by the IQ DILI Initiative in collaboration with DILI experts from academia and regulatory agencies. Recommended best practices are outlined pertaining to hepatic inclusion and exclusion criteria, monitoring of liver tests, ILICI detection, approach to a suspected ILICI signal, causality assessment, hepatic discontinuation rules and additional medical treatment., (Copyright © 2020 The Authors. Published by Elsevier Ltd.. All rights reserved.)
- Published
- 2020
- Full Text
- View/download PDF
48. Organic Cation Transporters in Human Physiology, Pharmacology, and Toxicology.
- Author
-
Samodelov SL, Kullak-Ublick GA, Gai Z, and Visentin M
- Subjects
- Biological Transport, Humans, Hydrogen-Ion Concentration, Intestinal Absorption, Organic Cation Transport Proteins genetics, Pharmacokinetics, Renal Reabsorption, Lipid Bilayers metabolism, Organic Cation Transport Proteins metabolism, Pharmaceutical Preparations metabolism, Toxins, Biological pharmacokinetics
- Abstract
Individual cells and epithelia control the chemical exchange with the surrounding environment by the fine-tuned expression, localization, and function of an array of transmembrane proteins that dictate the selective permeability of the lipid bilayer to small molecules, as actual gatekeepers to the interface with the extracellular space. Among the variety of channels, transporters, and pumps that localize to cell membrane, organic cation transporters (OCTs) are considered to be extremely relevant in the transport across the plasma membrane of the majority of the endogenous substances and drugs that are positively charged near or at physiological pH. In humans, the following six organic cation transporters have been characterized in regards to their respective substrates, all belonging to the solute carrier 22 (SLC22) family: the organic cation transporters 1, 2, and 3 (OCT1-3); the organic cation/carnitine transporter novel 1 and 2 (OCTN1 and N2); and the organic cation transporter 6 (OCT6). OCTs are highly expressed on the plasma membrane of polarized epithelia, thus, playing a key role in intestinal absorption and renal reabsorption of nutrients (e.g., choline and carnitine), in the elimination of waste products (e.g., trimethylamine and trimethylamine N-oxide), and in the kinetic profile and therapeutic index of several drugs (e.g., metformin and platinum derivatives). As part of the Special Issue Physiology, Biochemistry, and Pharmacology of Transporters for Organic Cations, this article critically presents the physio-pathological, pharmacological, and toxicological roles of OCTs in the tissues in which they are primarily expressed.
- Published
- 2020
- Full Text
- View/download PDF
49. The Role of Mitochondria in Drug-Induced Kidney Injury.
- Author
-
Gai Z, Gui T, Kullak-Ublick GA, Li Y, and Visentin M
- Abstract
The kidneys utilize roughly 10% of the body's oxygen supply to produce the energy required for accomplishing their primary function: the regulation of body fluid composition through secreting, filtering, and reabsorbing metabolites and nutrients. To ensure an adequate ATP supply, the kidneys are particularly enriched in mitochondria, having the second highest mitochondrial content and thus oxygen consumption of our body. The bulk of the ATP generated in the kidneys is consumed to move solutes toward (reabsorption) or from (secretion) the peritubular capillaries through the concerted action of an array of ATP-binding cassette (ABC) pumps and transporters. ABC pumps function upon direct ATP hydrolysis. Transporters are driven by the ion electrochemical gradients and the membrane potential generated by the asymmetric transport of ions across the plasma membrane mediated by the ATPase pumps. Some of these transporters, namely the polyspecific organic anion transporters (OATs), the organic anion transporting polypeptides (OATPs), and the organic cation transporters (OCTs) are highly expressed on the proximal tubular cell membranes and happen to also transport drugs whose levels in the proximal tubular cells can rapidly rise, thereby damaging the mitochondria and resulting in cell death and kidney injury. Drug-induced kidney injury (DIKI) is a growing public health concern and a major cause of drug attrition in drug development and post-marketing approval. As part of the article collection "Mitochondria in Renal Health and Disease," here, we provide a critical overview of the main molecular mechanisms underlying the mitochondrial damage caused by drugs inducing nephrotoxicity., (Copyright © 2020 Gai, Gui, Kullak-Ublick, Li and Visentin.)
- Published
- 2020
- Full Text
- View/download PDF
50. Medication as a risk factor for hospitalization due to heart failure and shock: a series of case-crossover studies in Swiss claims data.
- Author
-
Jödicke AM, Burden AM, Zellweger U, Tomka IT, Neuer T, Roos M, Kullak-Ublick GA, Curkovic I, and Egbring M
- Subjects
- Aged, Aged, 80 and over, Cross-Over Studies, Drug Utilization, Female, Heart Failure epidemiology, Humans, Insurance, Health, Male, Risk Factors, Shock epidemiology, Switzerland epidemiology, Amoxicillin-Potassium Clavulanate Combination therapeutic use, Anti-Bacterial Agents therapeutic use, Anti-Inflammatory Agents, Non-Steroidal therapeutic use, Heart Failure drug therapy, Hospitalization statistics & numerical data, Potassium therapeutic use, Shock drug therapy
- Abstract
Purpose: Heart failure is among the leading causes for hospitalization in Europe. In this study, we evaluate potential precipitating factors for hospitalization for heart failure and shock., Methods: Using Swiss claims data (2014-2015), we evaluated the association between hospitalization for heart failure and shock, and prescription of oral potassium supplements, non-steroidal anti-inflammatory drugs (NSAIDs), and amoxicillin/clavulanic acid. We conducted case-crossover analyses, where exposure was compared for the hazard period and the primary control period (e.g., 1-30 days before hospitalization vs. 31-60 days, respectively). Conditional logistic regression was applied and subsequently adjusted for addressing potential confounding by disease progression. Sensitivity analyses were conducted and stratification for co-medication was performed., Results: We identified 2185 patients hospitalized with heart failure or shock. Prescription of potassium supplements, NSAIDs, and amoxicillin/clavulanic acid was significantly associated with an increased risk for hospitalization for heart failure and shock with crude odds ratios (OR) of 2.04 for potassium (95% CI 1.24-3.36, p = 0.005, 30 days), OR 1.8 for NSAIDs (95% CI 1.39-2.33, p < 0.0001, 30 days), and OR 3.25 for amoxicillin/clavulanic acid (95% CI 2.06-5.14, p < 0.0001, 15 days), respectively. Adjustment attenuated odds ratios, while the significant positive association remained (potassium OR 1.70 (95% CI 1.01-2.86, p = 0.046), NSAIDs OR 1.50 (95% CI 1.14-1.97, p = 0.003), and amoxicillin/clavulanic acid OR 2.26 (95% CI 1.41-3.62, p = 0.001)., Conclusion: Prescription of potassium supplements, NSAIDs, and amoxicillin/clavulanic acid is associated with increased risk for hospitalization. Underlying conditions such as pain, electrolyte imbalances, and infections are likely contributing risk factors. Physicians may use this knowledge to better identify patients at risk and adapt patient management.
- Published
- 2020
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.